Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Leishmania major | ferric reductase, putative | 0.0106 | 0.2544 | 0.5 |
Echinococcus granulosus | geminin | 0.0146 | 0.3826 | 0.3826 |
Schistosoma mansoni | hypothetical protein | 0.0146 | 0.3826 | 1 |
Trypanosoma cruzi | ferric reductase transmembrane protein, putative | 0.0106 | 0.2544 | 0.5 |
Trypanosoma brucei | ferric reductase transmembrane protein, putative | 0.0106 | 0.2544 | 0.5 |
Treponema pallidum | hypothetical protein | 0.003 | 0.0142 | 0.5 |
Brugia malayi | Blistered cuticle protein 3 | 0.0226 | 0.6346 | 1 |
Toxoplasma gondii | histone lysine methyltransferase SET/SUV39 | 0.0026 | 0 | 0.5 |
Echinococcus multilocularis | geminin | 0.0146 | 0.3826 | 1 |
Loa Loa (eye worm) | pre-SET domain-containing protein family protein | 0.018 | 0.4886 | 0.7699 |
Onchocerca volvulus | 0.0205 | 0.5674 | 0.8941 | |
Loa Loa (eye worm) | hypothetical protein | 0.012 | 0.2984 | 0.4702 |
Onchocerca volvulus | Dual oxidase homolog | 0.0226 | 0.6346 | 1 |
Loa Loa (eye worm) | blistered cuticle protein 3 | 0.0226 | 0.6346 | 1 |
Trichomonas vaginalis | set domain proteins, putative | 0.0205 | 0.5674 | 0.5 |
Entamoeba histolytica | hypothetical protein | 0.003 | 0.0142 | 0.5 |
Brugia malayi | Pre-SET motif family protein | 0.018 | 0.4886 | 0.7699 |
Trypanosoma cruzi | ferric reductase transmembrane protein, putative | 0.0106 | 0.2544 | 0.5 |
Schistosoma mansoni | hypothetical protein | 0.0146 | 0.3826 | 1 |
Plasmodium vivax | SET domain protein, putative | 0.0026 | 0 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
EC50 (binding) | > 30 uM | Activation of Kv7.1 channel expressed in CHO cells assessed as depolarization-induced thallium influx after 3 mins by patch clamp assay | ChEMBL. | 22910039 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.